LON:INDV Indivior (INDV) Share Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Indivior Stock (LON:INDV) Get Indivior alerts:Sign Up Key Stats Today's Range N/A50-Day Range 1,238▼ 1,23852-Week Range N/AVolume8.46 million shsAverage Volume798,658 shsMarket Capitalization£1.93 billionP/E RatioN/ADividend Yield4.48%Price TargetN/AConsensus RatingN/A Company Overview Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia. Read More Receive INDV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Indivior and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INDV Stock News HeadlinesIndivior (LON:INDV) Stock Crosses Above Fifty Day Moving Average - Here's What HappenedJuly 21, 2026 | americanbankingnews.comReasons Why Investors Should Consider Betting on Indivior StockJune 25, 2026 | finance.yahoo.comUniversal basic income is not impossible. It exist (kind of)Robert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income Plan - direct ownership in 14 entities controlling U.S. pipelines, terminals, and processing plants, targeting 10% annually. The plan issues 42 payouts per year and is on pace to distribute $53 billion in 2025 - a record. The next distribution drops in days.July 26 at 1:00 AM | Freedom Financial (Ad)IBD 50 stock Indivior breaks out amid big fund ownership expansion, strong profit prospectsJune 25, 2026 | msn.comA Look At Indivior Pharmaceuticals (INDV) Valuation After Strong Multi Period Share Price GainsJune 10, 2026 | finance.yahoo.comAnalysts Are Bullish on Top Healthcare Stocks: Elevance Health (ELV), Indivior (INDV)June 5, 2026 | theglobeandmail.comIndivior Pharmaceuticals Inc. (INDV) is a great choice for 'trend' investors, here's whyMay 18, 2026 | msn.comIndivior Pharmaceuticals Inc Ordinary Share INDVMay 13, 2026 | morningstar.comMSee More Headlines INDV Stock Analysis - Frequently Asked Questions How do I buy shares of Indivior? Shares of INDV stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Indivior own? Based on aggregate information from My MarketBeat watchlists, some other companies that Indivior investors own include Futura Medical (FUM), Bigblu Broadband (BBB), Directa Plus (DCTA), Lakehouse (LAKE), Kingfisher (KGF), Sirius XM (SIRI) and Aquila Services Group (AQSG). Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryPharmaceutical Products Current SymbolLON:INDV CIKN/A Webindivior.com Phone+44-1753-217800FaxN/AEmployees1,000Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (1.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth-5.57Net Income-£2.36 million Net Margins11.44% Pretax MarginN/A Return on Equity-23.90% Return on Assets2.37% Debt Debt-to-Equity Ratio-141.86 Current Ratio0.90 Quick Ratio1.52 Sales & Book Value Annual Sales£1.40 billion Price / Sales0.00 Cash FlowN/A Price / Cash Flow2.68 Book ValueGBX (126.42) per share Price / BookN/AMiscellaneous Outstanding Shares156,209,528Free FloatN/AMarket Cap£1.93 billion OptionableNot Optionable Beta0.19 Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (LON:INDV) was last updated on 7/26/2026 by MarketBeat.com Staff. From Our PartnersThe comeback story of the century (ticker inside)In 2013, this struggling PC maker went private amid skepticism from Forbes and the New York Times. Instead of ...InvestorPlace | SponsoredUniversal basic income is not impossible. It exist (kind of)Robert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income P...Freedom Financial | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThis tiny piece of glass could be bigger than GPUsJensen Huang says AI can't scale without it. Google Ventures calls it the future of AI compute. Sequoia Capita...Brownstone Research | SponsoredOxford Club Analyst’s Urgent AI WarningAlexander Green, Chief Investment Strategist at The Oxford Club, is sharing a private presentation with a warn...The Oxford Club | SponsoredThe 90%-off options that empty accountsA call that cost $3.00 last month now trades for $0.30 - a 90% discount that looks tempting. It's not a bar...Profits Run | SponsoredHave you seen Elon’s new “supercurrency”? (It affects you)Elon Musk just became the world's first trillionaire following the biggest IPO in history, giving him access t...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Indivior PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Indivior With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
